Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
Recruiting · NCT06170970 · Registry updated 2026-06-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Solriamfetol for the Treatment of Multiple Sclerosis Fatigue | CNS demyelinating autoimmune disease, Disorders of Excessive Somnolence, Dyssomnias, Fatigue, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Sleep Disorders, Intrinsic, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, psychiatric disorder, sleep-wake disorder | Recruiting | Phase 2 | 2026-06-09 | NCT06170970 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Axsome Therapeutics, Inc. | 14 |
| Johns Hopkins University | 579 |
| National Multiple Sclerosis Society | 13 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Johns Hopkins University | Baltimore | United States | 150 |